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Abstract 
Type 2 diabetes mellitus (T2D), characterised by peripheral insulin resistance, is a risk factor for dementia. In addition 
to its contribution to small and large vessel disease, T2D may directly damage cells of the brain neurovascular unit. In 
this study, we investigated the transcriptomic changes in cortical neurones, and associated astrocytes and endothelial 
cells of the neurovascular unit, in the ageing brain. Neurone, astrocyte, and endothelial cell-enriched mRNA, obtained 
by immuno-laser capture microdissection of temporal cortex (Brodmann area 21/22) from 6 cases with self-reported 
T2D in the Cognitive Function and Ageing Study neuropathology cohort, and an equal number of age and sex-
matched controls, was assessed by microarray analysis. Integrated Molecular Pathway Level Analysis was performed 
using the Kyoto Encyclopaedia of Genes and Genomes database on significantly differentially expressed genes, 
defined as P < 0.05 and fold-change ± 1.2. Hub genes identified from Weighted Gene Co-expression Network Analy-
sis were validated in neurones using the NanoString nCounter platform. The expression and cellular localisation of 
proteins encoded by selected candidate genes were confirmed by immunohistochemistry. 912, 2202, and 1227 genes 
were significantly differentially expressed between cases with self-reported T2D and controls in neurones, astrocytes, 
and endothelial cells respectively. Changes in cortical neurones included alterations in insulin and other signalling 
pathways, cell cycle, cellular senescence, inflammatory mediators, and components of the mitochondrial respiratory 
electron transport chain. Impaired insulin signalling was shared by neurovascular unit cells with, additionally, apop-
totic pathway changes in astrocytes and dysregulation of advanced glycation end-product signalling in endothelial 
cells. Transcriptomic analysis identified changes in key cellular pathways associated with T2D that may contribute to 
neuronal damage and dysfunction. These effects on brain cells potentially contribute to a diabetic dementia, and may 
provide novel approaches for therapeutic intervention.
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Introduction
Type 2 diabetes mellitus (T2D), characterised by periph-
eral insulin resistance (IR), is an increasing problem in 
affluent societies. T2D increases with age and is associ-
ated with multiple organ complications. It is related to 
metabolic syndrome (MS), which includes central obe-
sity, hypertension, hyperglycaemia, raised serum tri-
glycerides, and lowered serum levels of high-density 
lipoprotein [1].
T2D/MS is an important risk factor for dementia [55]. 
T2D/MS is also a risk factor for vascular dementia (VaD) 
and Alzheimer’s disease (AD), although the evidence for 
the latter is less clear [11, 60], and T2D does not appear 
to be associated with increased AD neuropathological 
changes [4, 33]. Importantly, whereas the major causes 
of dementia are currently untreatable, some cases of 
dementia may be accounted for by risk factors that can 
be modified. Work on the United Kingdom population-
based Cognitive Function and Ageing Study (CFAS) 
neuropathology cohort suggests that up to a third of AD 
cases are attributable to modifiable risk factors, including 
T2D/MS and midlife obesity, with attributable risks for 
AD in the United Kingdom of 1.9% and 6.6%, respectively 
[43]. However, a recent systematic review did not find 
that various treatment strategies for T2D, aimed at sys-
temic glycaemic control, affect cognitive outcome [47].
The brain neurovascular unit (NVU), comprising cer-
ebral endothelium, pericytes, astrocytes, and neurones, 
is an important functional unit involved in homeostasis, 
through regulation of the blood–brain barrier, and neu-
ronal function through astrocytic neuronal support and 
neurovascular coupling [23]. Changes to the NVU are of 
increasing importance in neurodegeneration [71], and 
in  vivo imaging studies have shown that alterations to 
neurovascular coupling occur early in T2D [15]. In addi-
tion to its contribution to small and large vessel disease, 
T2D may affect the brain NVU through a number of 
candidate mechanisms. T2D/MS is associated with sys-
temic metabolic abnormalities [16, 35], and endothelial 
pathology in the periphery can result from inflammation, 
oxidative stress, hyperglycaemia, and signalling abnor-
malities [46]. The hyperglycaemia of T2D/MS can result 
in carbonyl stress, causing glycation with the formation 
of advanced glycation end-products (AGEs), which may 
interact with receptors for AGEs (RAGEs), and cause 
inflammation and oxidative stress [54, 61]. AGE forma-
tion may also increase beta-amyloid (Aβ) pathology and 
tau phosphorylation [3]. IR is a characteristic feature of 
T2D/MS. There appears to be a relationship between 
peripheral and central IR [69]. Neuronal IR has also been 
found in AD [37, 57], and reduced insulin signalling can 
increase tau phosphorylation in experimental models 
[10]. However, Aβ molecular pathology may also affect 
insulin signalling [56, 70]. Amylin (islet amyloid polypep-
tide), which accumulates in pancreatic islets in T2D/MS, 
may accumulate in the brain and contribute to AD patho-
genesis [5].
It is possible, therefore, that T2D/MS directly damages 
cells of the brain NVU, in addition to its effects on arter-
ies and microvasculature. Whilst changes to neurones 
have long been considered central to dementia pathology, 
astrocyte cellular pathology is also recognised as being 
important [20], whilst endothelial cells and microvascu-
lar function are thought to be affected early in AD and to 
contribute to its development [12, 25, 42].
However, these potential mechanisms of brain cell 
damage in T2D/MS remain poorly understood. We 
therefore investigated the transcriptomic changes in 
cortical neurones in donated brains from individuals 
with self-reported T2D compared to those without. We 
also investigated the concurrent changes in astrocytes 
and endothelial cells, to set the neuronal changes in the 
context of the brain NVU. We used donated brain tissue 
from the CFAS neuropathology cohort. CFAS is a longi-
tudinal study of cognitive impairment and frailty in the 
over-65 age group, with a population-representative neu-
ropathology cohort [8, 36, 66]. We identified changes in 
key cellular pathways that might contribute to neuronal 
damage and dysfunction, potentially contributing to a 
diabetic dementia.
Materials and methods
Human central nervous system tissue
Post-mortem lateral temporal cortex (Brodmann area 
21/22) was obtained from the CFAS neuropathol-
ogy cohort (www.cfas.ac.uk) [66], in accordance with 
Research Ethics Committee approval (15/SW/0246). 
Six cases with self-reported T2D, a group size consid-
ered adequate for gene expression studies [44, 59], and 
an equal number of age and sex-matched controls were 
selected to have minimal AD neuropathology, as defined 
by low Braak neurofibrillary tangle stage (stage 0–II) 
[6], without confounding pathologies (Table 1). Demen-
tia status at death was assessed using an algorithmic 
approach, as previously described [66]; this was not used 
for case selection. A tissue pH cut-off of 6.0 was used, 
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consistent with previous studies [38, 58]. The mean brain 
pH was 6.6 (standard deviation [SD] 0.4; range 6.1–7.3). 
The median post-mortem interval (PMI) was 32.3  h 
(interquartile range 16–36  h). The average age at death 
was 79.3 years (SD 7.2 years; range 73–92 years).
Immuno‑laser capture microdissection
Neurones, astrocytes, and capillary endothelial cells were 
isolated from separate sections of the same frozen blocks 
of lateral temporal cortex, using rapid immuno-laser 
capture microdissection (LCM), which preserves RNA 
quality sufficiently for array analysis, as described previ-
ously [53, 63]. This method produces cell-type enriched, 
but not pure, samples. Toluidine blue-stained neurones, 
glial fibrillary acidic protein (GFAP)-stained astrocytes, 
and collagen IV-stained endothelial cells were isolated 
from each case using the PixCell II LCM System (Arc-
turus Engineering, Mountain View, CA, USA) (Table 2). 
Total RNA was extracted using  PicoPure® RNA Isola-
tion Kits (Arcturus BioScience, Mountain View, CA, 
USA), according to the manufacturer’s protocol, with 
typical yields of 86.0 ng (SD 2.5 ng; range 52.3–133.7 ng), 
148.4 ng (SD 2.8 ng; range 101.0–186.8 ng), and 141.2 ng 
(SD 8.0 ng; range 31.6–311.4 ng) of total RNA from neu-
rones, astrocytes, and endothelial cells, respectively. The 
concentration and purity (A260/A280 ratio) of the total 
RNA were measured using the NanoDrop 1000 Spectro-
photometer (Thermo Scientific, Wilmington, DE, USA). 
The quality of the total RNA was assessed using the 2100 
Bioanalyser with RNA 6000 Pico LabChip Kits (Agilent, 
Palo Alto, CA, USA).
RNA amplification and microarray hybridisation
Linear amplification of total RNA was performed fol-
lowing Eberwine’s procedure [62], using GeneChip™ 3′ 
IVT Pico Kits (Applied Biosystems, Warrington, UK). 
Total RNA (10.0  ng) was reverse-transcribed to synthe-
sise the first-strand of complementary DNA (cDNA), 
using primers containing a T7 promoter sequence. Sin-
gle-stranded cDNA was converted into double-stranded 
cDNA, using DNA polymerase and RNase H, to simul-
taneously degrade the RNA and synthesise the second-
strand of cDNA. Double-stranded cDNA was used as 
the template for an overnight in vitro transcription (IVT) 
reaction to synthesise anti-sense RNA (complementary 
RNA [cRNA]), using T7 RNA polymerase. In the second 
cycle of cDNA synthesis, random primers were used to 
reverse-transcribe the cRNA, to obtain sense-strand 
cDNA. The quality of the cRNA and double-stranded 
cDNA were assessed using the 2100 Bioanalyser with 
RNA 6000 Pico LabChip Kits (Agilent, Palo Alto, CA, 
USA).
According to the manufacturer’s instructions, 6.6 µg of 
purified double-stranded cDNA was fragmented using 
uracil-DNA glycosylase (UDG) and apurinic/apyrimi-
dinic endonuclease 1 (APE1), and biotin-labelled with 
terminal deoxynucleotidyl transferase (TdT), using the 
Affymetrix proprietary DNA Labelling Reagent. The 
labelled cDNA was hybridised onto Human Genome 
U133 Plus 2.0  GeneChipⓇ Arrays (16  h at 45  °C, with 
rotation at 60  rpm) (Affymetrix UK, High Wycombe, 
UK), containing 54,000 probe sets, coding for > 47,000 
transcripts and variants, including 38,500 unique human 
genes.
Post-hybridisation washing and staining were per-
formed using the Affymetrix Fluidics Station 450 and 
Affymetrix  GeneChipⓇ Operating Software (GCOS). The 
arrays were scanned using the Affymetrix  GeneChipⓇ 
3000 7G Scanner. Hybridisation quality was determined 
Table 2 Antibody source and specificity
AGE, advanced glycation end-product; COL4, collagen IV; COX5b, cytochrome C oxidase subunit 5B; EDTA, ethylenediaminetetraacetic acid; FOXO3a, forkhead box 
O3; GFAP, glial fibrillary acid protein; IGF-1Rβ, insulin-like growth factor 1 receptor beta; IgG, immunoglobulin G; MW, microwave; N/A, not applicable (frozen tissue); 
NDUFb6, NADH:ubiquinone oxidoreductase subunit B6; O/N, overnight; p53, tumour protein p53; PC, pressure cooker; RT, room temperature; TB, toluidine blue; 
TGFβ1, transforming growth factor beta 1; TSC, trisodium citrate; γH2AX, gamma H2A histone family member X
Antibody Isotype Dilution (time, temp) Antigen retrieval Supplier
AGE Rabbit IgG 1:2000 (60 min, RT) MW 10 min, TSC Abcam, UK
COL4 Rabbit IgG 1:200 (3 min, RT) N/A Abcam, UK
COX5b Rabbit IgG 1:50 (60 min, RT) MW 10 min, EDTA Thermo Fisher Scientific, UK
FOXO3a Rabbit IgG 1:100 (O/N, 4 °C) PC, TSC Abcam, UK
GFAP Rabbit IgG 1:50 (3 min, RT) N/A Dako
γH2AX Rabbit IgG 1:2000 (60 min, RT) PC, EDTA R&D Systems, UK
IGF-1Rβ Rabbit IgG 1:25 (60 min, RT) N/A Santa Cruz Biotechnology, UK
NDUFb6 Rabbit IgG 1:100 (60 min, RT) MW 10 min, EDTA Sigma-Aldrich, UK
p53 Mouse IgG 1:50 (O/N, 4 °C) PC, MenaPath Access Super Santa Cruz Biotechnology, UK
TGFβ1 Rabbit IgG 1:400 (60 min, RT) PC, EDTA Abcam, UK
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using Affymetrix Expression Console™ version 1.4.1.46 
(Affymetrix, Inc., Santa Clara, CA, USA).
One control, C6 (Table 1), yielded insufficient quanti-
ties of double-stranded cDNA for microarray hybridisa-
tion. The sample was repeated. It failed the amplification 
step twice and was excluded from downstream analysis.
Microarray analysis
Raw signal intensity (.CEL) files from 6 cases with self-
reported T2D and 5 age- and sex-matched controls were 
imported into Qlucore Omics Explorer version 3.4 (Qlu-
core AB, Lund, Sweden). Normalisation was performed 
using the Robust Multi-array Average (RMA) algorithm 
[24, 34]. Two-group comparisons were conducted using 
a two-tailed, unpaired Student’s t test, without perform-
ing a correction for multiple testing. Significantly differ-
entially expressed genes (DEGs) were identified using an 
unadjusted P < 0.05 and a fold-change (FC) threshold of 
plus or minus 1.2. Comparisons were drawn using jVenn: 
an interactive Venn diagram viewer (http://jvenn .toulo 
use.inra.fr) [2].
Integrated molecular pathway level analysis
A Wilcoxon pathway enrichment analysis, based on gene 
symbol and FC, was performed for each cell type using 
Integrated Molecular Pathway Level Analysis (IMPaLA) 
version 11, build April 2018 (http://impal a.molge n.mpg.
de/) [27]. For genes with multiple probe sets, the mean 
FC was used. Significantly enriched pathways in the 
Kyoto Encyclopaedia of Genes and Genomes (KEGG) 
database (https ://www.genom e.jp/kegg/) [28, 29] were 
identified using an unadjusted P < 0.05 (Additional file 4: 
Table S1).
Weighted gene co‑expression network analysis
Weighted gene co-expression network analysis 
(WGCNA) was performed using the GeneMANIA 
plugin [39] for Cytoscape version 3.7.2 (Cytoscape Con-
sortium, San Diego, CA, USA) [49]. Networks were cre-
ated using the IMPaLA-generated lists of DEGs enriched 
in KEGG pathways associated with (1) Diabetes and 
dementia (n = 73, P < 0.05) (Additional file  1: Fig. S1), 
(2) Diabetic complications (n = 101, P < 0.05) (Addi-
tional file 2: Fig. S2), (3) DNA damage response (n = 87, 
P < 0.05) (Additional file  3: Fig. S3a), and (4) Autophagy 
(n = 31, P < 0.001) (Additional file  3: Fig. S3b). The Dia-
betes and dementia network included insulin signalling, 
AGE-RAGE signalling in diabetic complications, and 
Alzheimer disease. The Diabetic complications network 
included AGE-RAGE signalling in diabetic complica-
tions, chemokine signalling (inflammation), hypoxia 
inducible factor-1 (HIF-1) signalling, fluid shear stress 
and atherosclerosis, and non-alcoholic fatty liver disease 
(NAFLD). The DNA damage response network included 
cell cycle, cellular senescence, p53 signalling, apoptosis, 
and necroptosis (inflammatory cell death). The brain 
NVU was analysed as a whole. Network weighting was 
assigned based on query genes, so as to maximise con-
nectivity among input genes. The maximum number of 
related genes or attributes was zero [18, 65]. Two gene 
products are linked in red, if they participated in the 
same reaction within a pathway [67]. The strengths of 
relationships are represented by the intensity of the col-
our and the thickness of the interconnecting lines.
Microarray validation in neurones: NanoString nCounter 
platform
Hub genes identified through WGCNA were validated 
using NanoString nCounter XT CodeSet Gene Expres-
sion Assays (NanoString Technologies, Seattle, WA, 
USA). A custom CodeSet (C6959X1) was designed in 
consultation with the NanoString Bioinformatics team 
and manufactured by NanoString Technologies (Addi-
tional file 5: Table S2). The CodeSet was created by com-
bining 69 probe sets from NanoString’s commercially 
available nCounter Human Neuropathology and nCoun-
ter Human Inflammation panels. Actin, beta (ACTB), 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 
and ribosomal protein, large, P0 (RPLP0) were selected 
as housekeeping genes, based on the stability of their 
expression in the microarray study. Twenty-eight genes 
were included from the Diabetes and dementia network 
(Additional file 1: Fig. S1), 42 from the Diabetic compli-
cations network (Additional file  2: Fig. S2), 37 from the 
DNA damage response network (Additional file  3: Fig. 
S3a), and 11 from the Autophagy network (Additional 
file 3: Fig. S3b), with 32 genes common to two or more 
networks. The nCounter Analysis System uses molecu-
lar ‘barcodes’ and single-molecule imaging to detect and 
count hundreds of unique transcripts in a single reac-
tion. Each colour-coded barcode is covalently attached to 
a single target-specific probe corresponding to a gene of 
interest. Mixed together with controls, they form a multi-
plexed CodeSet [21, 22, 32].
Total RNA, approximately 165.0 ng (SD 23.3 ng; range 
126.5–202.8 ng), was concentrated to a volume of 5.0 µL, 
using a miVac DNA concentrator (GeneVac Ltd., Suffolk, 
UK), with the temperature set at 31 °C. After an overnight 
hybridisation (16 h at 65  °C in a thermocycler) with the 
target-specific biotinylated capture probes and barcode-
containing reporter probes in solution, excess probes 
were removed, and target-probe complexes immobi-
lised and aligned in the nCounter cartridge, which was 
loaded into the nCounter SPRINT™ Profiler (NanoString 
Technologies, Seattle, WA, USA) for image acquisition 
and data processing. Gene expression was measured by 
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counting the number of times the colour-coded barcode 
for each gene was detected.
NanoString analysis of neurones
Reporter Code Count (RCC) files were imported into 
nSolver™ Analysis Software 4.0 (NanoString Technolo-
gies, Seattle, WA, USA). The manufacturer’s recom-
mended default parameters for quality control flagging 
were used for imaging (field of view registration, < 75%), 
binding density (< 0.1 or > 2.25), positive control linearity 
(R2 value < 0.95), and positive control limit of detection 
(0.5 fM positive control ≤ 2 SD above the mean of the 
negative controls). The background threshold was calcu-
lated using the geometric mean of the negative controls. 
Each sample was first normalised to the geometric mean 
of the positive controls (with default flagging of normali-
sation factors, < 0.3 and > 3), followed by normalisation to 
the geometric mean of the housekeeping genes, ACTB, 
GAPDH, and RPLP0 (with default flagging of normalisa-
tion factors, < 0.1 and > 10). Differential expression was 
evaluated using the nCounter Advanced Analysis plugin 
version 2.0.115 (NanoString Technologies, Seattle, WA, 
USA). Statistical significance was determined using an 
unadjusted P < 0.05.
Immunohistochemical validation of protein expression
To confirm the expression and cellular localisation of 
proteins encoded by selected candidate genes, immu-
nohistochemical staining of sections of lateral temporal 
cortex from the same cases as the microarray cohort was 
performed, using a standard horseradish peroxidase-con-
jugated avidin–biotin complex method, using Vectastain 
Elite Kits (Vector Laboratories, Peterborough, UK). Per-
oxidase activity was detected using diaminobenzidine 
(Vector Laboratories, Peterborough, UK). The primary 
antibodies used and their experimental conditions are 
summarised in Table 2.
Results
Enrichment of neuronal, astrocytic, and endothelial cell 
populations
Neurofilament protein, light chain (NEFL) and neurofila-
ment protein, heavy chain (NEFH) were highly expressed 
in neurones compared with astrocytes and endothelial 
cells. Von Willebrand factor (VWF), platelet and endothe-
lial cell adhesion molecule 1 (PECAM1), and intercel-
lular adhesion molecule 1 (ICAM1) were moderately 
expressed in endothelial cells compared with neurones 
and astrocytes. These findings suggest that the RNA iso-
lated by immuno-LCM from toluidine blue-stained neu-
rones and collagen IV-stained capillary endothelial cells 
represents an enriched neurone or endothelial cell popu-
lation, respectively. Astrocyte-specific markers, GFAP 
and excitatory amino acid transporter 2 (EAAT2), were 
similarly expressed in neurones, astrocytes, and endothe-
lial cells, reflecting the close proximity of astrocytes to 
the other cell types in the brain NVU (Additional file 6: 
Table S3).
Differentially expressed transcripts in the brain NVU 
of cases with self‑reported T2D
The transcription profiles of laser-captured neurones, 
astrocytes, and endothelial cells from the lateral temporal 
cortex of 6 cases with self-reported T2D and 5 age- and 
sex-matched controls were generated using Affymetrix 
Human Genome U133 Plus 2.0  GeneChipⓇ Arrays. 
The gene expression data set is freely available at Gene 
Expression Omnibus (accession number GSE:161355). 
Between 18.5% and 65.7% of the probe set sequences 
were present across all three cell types (mean [range]): 
neurones (54.2% [38.5–65.7%]), astrocytes (43.4% [26.3–
60.9%]), and endothelial cells (45.2% [18.5–61.5%]), 
respectively.
Transcripts were considered significantly, differentially 
expressed if they had a minimum FC of plus or minus 
1.2 and an unadjusted P < 0.05 (Student’s t-test). Nine 
hundred and twelve (567 up-regulated, 345 down-regu-
lated), 2202 (1144 up-regulated, 1058 down-regulated), 
and 1227 (757 up-regulated, 470 down-regulated) signifi-
cantly DEGs were identified in neurones, astrocytes, and 
endothelial cells, respectively (Fig. 1a). Principal compo-
nent analysis and hierarchical clustering demonstrated 
clear separation between cases with self-reported T2D 
(highlighted in yellow) and controls (highlighted in blue) 
(Fig. 1b).
A Venn diagram comparing the lists of significantly 
DEGs (Fig.  1c) showed little overlap between the dif-
ferent cell types of the brain NVU at the specific gene 
level (in contrast to findings from the pathway analy-
sis). Only 5 (0.1%) of the 4149 significantly DEGs were 
commonly dysregulated in neurones, astrocytes, and 
endothelial cells, namely DND microRNA-mediated 
repression inhibitor 1 (DND1 probe set id: 57739_at) 
(neurones: FC, +1.33 [P = 0.014]; astrocytes: FC, +1.56 
[P = 0.013]; endothelial cells: FC, +1.49 [P = 0.021]), 
leucine rich repeat containing 37A (LRRC37A probe 
set id: 239591_at) (neurones: FC, +2.09 [P = 0.034]; 
astrocytes: FC, +2.05 [P = 0.019]; endothelial cells: FC, 
+1.39 [P = 0.005]), NIMA related kinase 6 (NEK6 probe 
set id: 223561_at) (neurones: FC, +1.58 [P = 0.027]; 
astrocytes: FC, +2.26 [P = 1.52E−05]; endothelial cells: 
+1.62 [P = 0.025]), oral cancer overexpressed protein 1 
(ORAOV1 probe set id: 243531_at) (neurones: FC, +1.85 
[P = 0.049]; astrocytes: FC, +1.87 [P = 0.014]; endothelial 
cells: FC, +1.63 [P = 0.031]), and serpin family A mem-
ber 3 (SERPINA3 probe set id: 202376_at) (neurones: 
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Fig. 1 DEGs between T2D and control groups. a Volcano plots representing P value (−Log10 P value, vertical axis) and relative expression (FC, 
horizontal axis), b hierarchically clustered heat maps of DEGs in T2D [D] (yellow) versus controls [C] (blue), and c jVenn diagram comparing DEGs 
between different cell types of the NVU. Up-regulated (⇧ reg) genes are shown in red and down-regulated (⇩ reg) genes are shown in a green or b 
blue
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FC, +6.63 [P = 0.012]; astrocytes: FC, +4.10 [P = 0.018]; 
endothelial cells: FC, +3.50 [P = 0.009]). Forty-seven 
transcripts were commonly dysregulated in neurones and 
astrocytes (23 up-regulated, 6 down-regulated, 18 with 
opposite directions of change); 34 transcripts were com-
monly dysregulated in neurones and endothelial cells (17 
up-regulated, 7 down-regulated, 10 with opposite direc-
tions of change); and 101 transcripts were commonly 
dysregulated in astrocytes and endothelial cells (72 up-
regulated, 20 down-regulated, 9 with opposite directions 
of change).
IMPaLA pathway analysis identified 23, 65, and 34 
pathways in the KEGG database that were significantly 
enriched in neurones, astrocytes, and endothelial cells, 
respectively (Wilcoxon test, unadjusted P < 0.05) (Addi-
tional file 4: Table S1).
T2D‑associated changes in the cortical neurone 
transcriptome
Our further analysis focused on changes in path-
ways and functional groups, rather than individual 
DEGs. The neuronal transcriptomic profile indicated 
the significant dysregulation of several key signalling 
pathways associated with T2D, including phosphatidylin-
ositol-3-kinase (PI3K)-protein kinase B (Akt) signalling 
(19 DEGs, P = 4.27E−03), cellular senescence (7 DEGs, 
P = 0.016), cell cycle (9 DEGs, P = 0.024), Alzheimer 
disease (7 DEGs, P = 0.031), HIF-1 signalling (6 DEGs, 
P = 0.031), tumour necrosis factor (TNF) signalling (6 
DEGs, P = 0.031), oxidative phosphorylation (6 DEGs, 
P = 0.031), and insulin signalling (8 DEGs, P = 0.039) 
(Fig. 2).
Functional grouping identified marked dysregulation 
of multiple signalling cascades, including the activation 
of the PI3K-Akt signalling [forkhead box O 3 (FOXO3 
probe set id: 204131_s_at) (FC, +1.39; P = 0.020)], HIF-1 
signalling [BCL2 apoptosis regulator (BCL2 probe set id: 
203684_s_at) (FC, +1.36; P = 0.028); cytochrome B-245 
beta chain (CYBB probe set id: 203923_s_at) (FC, +2.74; 
P = 0.020)], TNF signalling [interleukin 6 (IL6 probe set 
id: 205207_at) (FC, +1.43; P = 0.043)], and insulin signal-
ling [glucose-6-phosphatase catalytic subunit 2 (G6PC2 
probe set id: 221453_at) (FC, +1.37; P = 0.032); phos-
phorylase kinase, alpha 1 (muscle) (PHKA1 probe set 
id: 205450_at) (FC, +1.96; P = 4.91E−03); protein tyros-
ine phosphatase non-receptor type 1 (PTPN1 probe set 
id: 217689_at) (FC, +1.70; P = 0.025); ribosomal protein 
S6 kinase B1 (RPS6KB1 probe set id: 204171_at) (FC, 
+1.33; P = 0.026); sorbin and SH3 domain-containing 
protein 1 (SORBS1 probe set id: 222513_s_at) (FC, +1.51; 
P = 2.85E−03)] pathways (Fig. 2).
Further interrogation of the cortical neurone transcrip-
tome identified dysregulation of genes implicated in the 
cell cycle and cellular senescence, including checkpoint 
kinase 1 (CHEK1 probe set id: 205394_at) (FC, +1.44; 
P = 0.025), cyclin-dependent kinase 1 (CDK1 probe set 
id: 210559_s_at) (FC, +1.52; P = 0.022), cell division 
cycle 14A (CDC14A probe set id: 210440_s_at) (FC, 
+2.13; P = 0.015), stromal antigen 1 (STAG1 probe set 
id: 202294_at) (FC, +1.44; P = 0.037), and transcription 
factors Dp-1 (TFDP1 probe set 242939_at) (FC, −1.30; 












Regulation of actin cytoskeleton*
Cytokine-cytokine receptor interaction*
Insulin signalling pathway*
Fig. 2 Neurone-enriched IMPaLA pathways in the KEGG database. Up-regulated genes are represented by the white bars and down-regulated 
genes are represented by the black bars. Signalling pathways, other includes PI3K-Akt, MAPK, Rap1, TNF, and retrograde endocannabinoid signalling 
pathways. *P < 0.05, **P < 0.01
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P = 0.047), and Dp-2 (TFDP2 probe set id: 226157_at) 
(FC, +1.34; P = 1.84E−03).
Pathway analysis also identified dysregulation of 
AD-related genes, including amyloid beta (A4) pre-
cursor protein-binding, family B, member 1 (APBB1 
probe set id: 202652_at) (FC, −1.64; P = 0.026) and 
membrane metalloendopeptidase (neprilysin) (MME 
probe set id: 203434_s_at) (FC, +1.37; P = 0.049). Spe-
cifically, there was down-regulation of mitochon-
drial respiratory electron transport chain-associated 
transcripts, including cytochrome C oxidase subu-
nit 5B (COX5B probe set id: 213735_s_at) (FC, −1.17; 
P = 0.095) and NADH:ubiquinone oxidoreductase subu-
nits A1 (NDUFA1 probe set id: 202298_at) (FC, −1.46; 
P = 0.014), A8 (NDUFA8 probe set id: 218160_at) (FC, 
−1.56; P =0.012), B3 (NDUFB3 probe set id: 203371_s_
at) (FC, −1.71; P = 0.029), and B6 (NDUFB6 probe set id: 
1559042_at) (FC, −1.50; P = 0.041).
Concurrent changes in the brain NVU: astrocyte 
and endothelial cell transcriptomes
To set the neuronal changes in the context of the brain 
NVU, we expanded our analysis to examine the concur-
rent pathway alterations in the astrocyte and endothelial 
cell transcriptomes. Significantly enriched KEGG path-
ways in the astrocyte transcriptome included insulin sig-
nalling (20 DEGs, P = 4.18E−04), autophagy (20 DEGs, 
P = 8.51E−04), apoptosis (14 DEGs, P = 5.23E−03), fluid 
shear stress and atherosclerosis (18 DEGs, P = 0.013), 
chemokine signalling (17 DEGs, P = 0.015), p53 signal-
ling (11 DEGs, P = 0.042), cell cycle (13 DEGs, P = 0.043), 
Non-alcoholic fatty liver disease (NAFLD, 17 DEGs, 
P = 0.047), and necroptosis (15 DEGs, P = 0.047) (sum-
marised in Fig. 3a; see Additional file 4: Table S1 for full 
listing). Significantly enriched KEGG pathways in the 
endothelial cell transcriptome also included insulin sig-
nalling (12 DEGs, P = 0.034) and fluid shear stress and 
atherosclerosis (9 DEGs, P = 9.03E−03), phospholipase 
D signalling (8 DEGs, P = 0.016) and AGE-RAGE signal-
ling in diabetic complications (10 DEGs, P = 5.89E−03) 
(Fig. 3b).
Validation of key neuronal targets
Neuronal expression of selected candidate genes identi-
fied through WGCNA was validated in the same cohort 
as the microarray, using the NanoString nCounter plat-
form. The same direction of change was confirmed for 63 
(91.3%) of the 69 genes in the custom C6959X1 CodeSet. 
Transcriptional alterations associated with T2D included 
the increased expression of DNA damage inducible tran-
script 3 (DDIT3 probe set id: 209383_at) (FC, +2.03; 
P = 0.036), H2A histone family, member X (H2AFX 
probe set id: 205436_s_at) (FC, +1.71; P = 2.80E−03), 
heme oxygenase 1 (HMOX1 probe set id: 203665_at) (FC, 
+8.38; P = 7.86E−03), and NAD(P)H quinone dehydro-
genase 1 (NQO1 probe set id: 201468_s_at) (FC, +2.26; 
P = 0.026), and the decreased expression of COX5B 
(probe set id: 213735_s_at) (FC, –1.17; P = 0.095), gluta-
mate ionotropic receptor NMDA type subunit 1 (GRIN1 
probe set id: 210781_x_at) (FC, –1.32; P = 0.024), and 
transferrin (TF probe set id: 220109_at) (FC, –1.59; 
P = 0.092) (Fig. 4).
The neuronal expression and cellular localisation of 
proteins encoded by selected candidate genes, namely 
COX5b, NDUFb6, transforming growth factor beta 1 
(TGFβ1), FOXO3a, and tumour protein p53 (p53), were 
confirmed by immunohistochemistry (Fig.  5a–e). Fur-
ther immunohistochemical analysis revealed positive 
staining for AGEs in all three cell types of the brain NVU 
(neurones, astrocytes, and endothelial cells), γH2AX in 
astrocytes, and insulin-like growth factor 1 receptor beta 
(IGF-1Rβ) in endothelial cells (Fig. 5f–h).
Discussion
Key findings
T2D is a major modifiable risk factor for dementia. 
Whilst some of this risk may be mediated via its effects 
on classical dementia-associated neuropathologies, par-
ticularly vascular disease, T2D may directly affect cells of 
the brain. To address this question, we examined changes 
in the neuronal transcriptome in neocortex associated 
with self-reported T2D using microarray-based gene 
expression analysis of RNA isolated from laser-captured 
neurones. Additionally we examined the transcrip-
tomes of astrocytes and endothelial cells to set the neu-
ronal changes in the context of the broader NVU and 
to determine whether the three cell types were similarly 
impacted by T2D. Laser-capture microdissection pro-
duces cell-type enriched, but not pure populations [53, 
63]. This was reflected in the astrocytic transcripts identi-
fied in neuronal and endothelial populations. We did not 
specifically examine pericytes, but given the resolution 
of laser capture microdissection these will also be repre-
sented in the “endothelial samples”, along with astrocytic 
processes so that endothelial enriched samples reflect the 
more complex cells of the microvasculature [40]. Meth-
ods such as RNA in situ hybridisation may be of value in 
future work to obtain clearer cell-type specific expression 
of candidate genes at higher resolution. This would allow 
separation of pericytic and endothelial signals, for exam-
ple, but our primary focus in this study was on the neu-
ronal changes.
The cases used were selected to have low levels of 
potentially confounding neuropathology. Gene expres-
sion analysis of the neuronal transcriptome showed 
separation of T2D from control cases with 912 DEGs. 
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Pathway analysis revealed changes in key neuronal path-
ways that are relevant to potential neuronal dysfunc-
tion in dementia, including signalling, cell cycle and 
senescence, and AD-related pathways. Gene expres-
sion changes were validated using NanoString as a sec-
ond independent method. Key pathway alterations 
were also identified in astrocytes and endothelial cells, 
including inflammation pathways, insulin signalling and 
AGE-RAGE signalling pathways. Although there was lit-
tle overlap in the DEGs between the three cell types at 
the individual gene level, some of the signalling pathway 
changes were shared, particularly insulin signalling which 
suggests that insulin signalling is widely dysregulated in 
the NVU.
Changes in the neuronal transcriptome
Identifying patterns of altered genes forming cellular 
pathways can potentially provide a more physiologically 
relevant picture of cellular alterations and be less sus-
ceptible to false discovery than individual genes. Using 
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Fig. 3 a Astrocyte- and b endothelial cell-enriched IMPaLA pathways in the KEGG database. Up-regulated genes are represented by the white bars 
and down-regulated genes are represented by the black bars. Signalling pathways, other includes a Sphingolipid, oxytocin, Rap1, neurotrophin, 
ErbB, phosphatidylinositol, MAPK, chemokine, T cell receptor, GnRH, Ras, AMPK, mTOR, PI3K-Akt, oestrogen, Wnt, and p53 and b PI3K-Akt, oxytocin, 
phospholipase D, GnRH, Rap1, MAPK, thyroid hormone, cGMP-PKG, and Wnt signalling pathways. *P < 0.05, **P < 0.01, ***P < 0.001
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this approach we have previously identified pathogeni-
cally relevant pathway alterations in the CFAS cohort 
in relation to oxidative DNA damage, astrocyte changes 
with AD neuropathology progression and in white mat-
ter lesions [50–52]. We therefore focused on changes in 
cellular pathways and functional groups. T2D can affect 
a variety of metabolic processes that can affect cell func-
tion, including insulin and other signalling pathways, glu-
cose metabolism and mitochondrial function, processes 
the may contribute to neuronal dysfunction [11]. Using 
pathway analysis, we have herein identified changes in 
signalling pathways, cell cycle and senescence, and AD-
related transcripts in neurones in association with T2D.
Signalling pathway alterations included changes in 
insulin, PI3K-Akt, HIF-1 and TNF signalling pathways 
suggesting that neuronal signalling is dysregulated in 
T2D. Alterations in neuronal insulin signalling have been 
implicated in the pathogenesis of AD and may affect the 
downstream PI3K-Akt pathway. There may be several 
mechanisms for reduced activation of the insulin sig-
nalling pathway in AD neurones, including the binding 
of Aβ to the insulin receptor and changes in the phos-
phorylation state of insulin receptor substrate 1 [37, 
57, 70]. Reduced expression of mRNAs for insulin (and 
other) signalling pathway molecules have been identi-
fied in astrocytes in association with the progression of 
AD neuropathological change [52]. Insulin resistance 
in neurones experimentally may also contribute to AD 
molecular pathology [10, 68]. We also identified reduced 
expression of insulin signalling pathway genes in associa-
tion with a DNA damage response in neurones in human 
autopsy tissue [51]. Impaired neuronal insulin signalling 
therefore appears to be an important common mecha-
nism in neurones. Results from this study suggest that 
neuronal insulin signalling is also affected in T2D, and 
most of the pathway components were up-regulated, 
which might imply a compensatory response to impaired 
insulin signalling.
Genes in the cell cycle and senescence pathways were 
also altered. Senescent cells show loss of function, may 
propagate damage through the senescence-associated 
secretory pathway and have been implicated in AD [64]. 
Senescent cells are also a potential therapeutic target, 
with the advent of senolytics [26, 30, 41]. Whether this 
may lead to neuronal senescence in T2D is therefore a 
pressing question.
Pathway analysis also revealed alteration in AD-related 
transcripts. These include Aβ-related transcripts and 
neprilysin, which is the dominant Aβ peptide-degrading 
enzyme in the brain [17]. Genes in this pathway also 
suggest down-regulation of mitochondrial genes, which 
may imply mitochondrial dysfunction. Mitochondrial 
dysfunction has been implicated in neurodegeneration 
including AD, as well as in diabetes and obesity [45]. 
Alterations in these pathways provide a potential point of 
intersection between T2D and AD neuropathology.
Cell pathway alterations in astrocytes and endothelial cells
We identified gene expression and cell pathway altera-
tions in astrocytes and endothelial cells that suggest they 
are also involved in T2D-related brain injury. There is 
increasing evidence for the importance of astrocytes in 
dementia and neurodegenerative disorders [13, 20] whilst 
endothelial cells are the interface between the brain and 
blood, and would be expected to be affected by T2D. In 
common with changes in neurones, pathway analysis 
also revealed changes in insulin signalling in astrocytes 
and endothelial cells, suggesting that insulin signalling 
dysregulation of the various cellular components of the 
NVU is a feature of T2D. These are changes that might 
be expected in diabetes providing further support for the 
relevance of pathway changes found. Insulin signalling 
Fig. 4 Validation of neurone microarray data using the NanoString 
nCounter Platform. Up-regulated genes are represented by the 
red circles and down-regulated genes are represented by the blue 
circles. The size of the circle indicates the significance of the P value. 
Colour intensity denotes the magnitude of the FC, fold-change; MA, 
microarray; NS, NanoString







Fig. 5 Immunohistochemical staining. a COX5b, Case D4; b NDUFb6, Case D6; c TGFβ1, Case D5; d FOXO3a, Case D5; e p53, Control C4; f AGE, Case 
D6; g γH2AX, Case D6; h IGF-1Rβ, Case D3. immunoreactivity in neurones (stars), astrocytes (arrows), and endothelial cells (open arrows) in lateral 
temporal cortex from CFAS cases in the microarray cohort. Magnification bars 50 μm
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impairment is a feature of neurones in AD, but this path-
way is also functional in astrocytes [19] and changes in 
this pathway have also been found in astrocytes with AD 
neuropathology progression [52], suggesting that these 
cells and possibly also cerebral endothelial cells may be 
affected by IR in T2D. The NAFLD pathway is also altered 
in astrocytes. Non-alcoholic fatty liver disease, recently 
renamed metabolic-associated fatty liver disease, is a fea-
ture of T2D and metabolic syndrome [31].The NAFLD 
pathway contains genes relevant to insulin signalling and 
mitochondrial function (Additional file 4: Table S1), fur-
ther suggesting metabolic and signalling dysregulation in 
astrocytes and links to peripheral dysmetabolism. Altera-
tions in autophagy, apoptosis, p53 signalling and cell 
cycle, suggest astrocyte injury and changes to proteosta-
sis. Astrocytes are an important source of glutamate for 
neurons as part of the tripartite synapse [20] and changes 
to genes involved in glutamate reuptake and cycling may 
imply a protective response from excitotoxicity. Endothe-
lial cells showed alterations in the AGE-RAGE signalling 
pathway, which has pleiotropic cellular effects and has 
been implicated in neuroinflammation and neurodegen-
eration [14]. AGE formation can result from abnormal 
glycation and we recently showed that it increases with 
AD neuropathological change, although it did not associ-
ate with dementia and the relationship of brain AGE for-
mation to T2D is yet to be defined [9]. AGE formation 
may therefore be one mechanism of endothelial damage 
in T2D. Changes in the cellular adherence pathway in 
endothelial cells could be a response to maintain blood–
brain barrier integrity. Overall, these changes suggest 
that T2D affects astrocytes and endothelial cells as well 
as neurons. These changes may contribute to NVU dys-
function, but may also reveal compensatory mechanisms.
Study limitations
The CFAS neuropathology cohort is population-repre-
sentative. However, this study used a case–control design 
nested within the larger population study. Cases were 
defined according to self-reported T2D status. However, 
defining T2D for retrospective studies and quantifying 
the severity and cumulative exposure to metabolic dys-
regulation are problematic [7]. Conversely, whilst our 
control group did not have self-reported T2D, we cannot 
exclude the possibility of subclinical T2D or undiagnosed 
metabolic syndrome. Such difficulties would require a 
prospective case–control cohort to resolve, with longitu-
dinal follow-up to provide a more integrated measure of 
in-life T2D/MS over a time course. Such a cohort would 
be valuable to further understand the effects of T2D/MS 
on the brain and for validation of the changes we have 
identified in a separate cohort. Given potential interac-
tions between T2D/MS and AD, it would also be of value 
to compare changes associated with each of these indi-
vidual pathologies and cases with combined pathology to 
determine the effects of interaction on the NVU.
A further limitation of this study was the number of 
cases available, a limitation imposed by the number of 
cases in the CFAS neuropathology cohort with self-
reported T2D, but with good quality RNA and without 
confounding pathologies. Whilst the number used here 
has detected significant changes in gene expression and 
in key cellular pathways, and similar numbers have gen-
erated robust results in previous studies [44, 59], some 
studies suggest that a larger number of cases is required 
to reliably detect all DEGs. For example, Schurch et  al. 
[48] reported that for RNA-sequencing gene expression 
studies, group sizes should be 12 or more to detect all 
DEGs. With a smaller number of cases in this study, it is 
possible that some significantly DEGs were not detected.
Conclusions
Most investigations into the effects of T2D on the brain 
have focused on interactions with vascular disease and 
AD. This study, using two methods to assess transcrip-
tomic changes, identified pathogenically relevant path-
way changes in cortical neurones in association with 
T2D, with changes in astrocytes and endothelial cells 
suggesting wider involvement of the NVU. A transcrip-
tomic approach, as used here, is a hypothesis gener-
ating approach that requires further investigation in 
separate cohorts and experimental systems. However, 
these changes offer potential new avenues for mechanis-
tic, biomarker and therapeutic studies. Neuronal gene 
expression and pathway alterations suggest dysregulation 
of signalling, cell injury, neuroinflammation and metabo-
lism suggesting potential mechanisms by which T2D may 
directly affect the brain, producing a diabetic dementia 
that is independent of but potentially interacting with 
vascular and AD neuropathology.
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Additional file 1 Fig. S1 Diabetes and Dementia Network. WGCNA of 
IMPaLA-generated lists of DEGs enriched in insulin signalling, AGE-RAGE 
signalling in diabetic complications, and Alzheimer disease pathways in 
the KEGG database. Hub genes included in the NanoString panel are high-
lighted in yellow. Targets which were validated by immunohistochemistry 
are indicated by the asterisks. Two gene products are linked in red, if they 
participated in the same reaction within a pathway. The strengths of rela-
tionships are represented by the intensity of the colour and the thickness 
of the interconnecting lines. Created using the GeneMANIA plugin for 
Cytoscape version 3.7.2
Additional file 2 Fig. S2 Diabetic Complications Network. WGCNA 
of IMPaLA-generated lists of DEGs enriched in AGE-RAGE signalling in 
diabetic complications, chemokine signalling, HIF-1 signalling, fluid shear 
Page 14 of 16Bury et al. acta neuropathol commun             (2021) 9:5 
stress and atherosclerosis, and NAFLD pathways in the KEGG database. 
Hub genes included in the NanoString panel are highlighted in yellow. 
Targets which were validated by immunohistochemistry are indicated 
by the asterisks. Two gene products are linked in red, if they participated 
in the same reaction within a pathway. The strengths of relationships 
are represented by the intensity of the colour and the thickness of the 
interconnecting lines. Created using the GeneMANIA plugin for Cytoscape 
version 3.7.2
Additional file 3 Fig. S3 (A) DNA Damage Response and (B) Autophagy 
Networks. WGCNA of IMPaLA-generated lists of DEGs enriched in (A) cell 
cycle, cellular senescence, p53 signalling, apoptosis, and necroptosis and 
(B) autophagy pathways in the KEGG database. Hub genes included in the 
NanoString panel are highlighted in yellow. Targets which were validated 
by immunohistochemistry are indicated by the asterisks. Two gene 
products are linked in red, if they participated in the same reaction within 
a pathway. The strengths of relationships are represented by the intensity 
of the colour and the thickness of the interconnecting lines. Created using 
the GeneMANIA plugin for Cytoscape version 3.7.2
Additional file 4 Table S1 IMPaLA-Enriched Pathways in the KEGG Data-
base. #, number; IMPaLA, Integrated Molecular Pathway Level Analysis; 
KEGG, Kyoto Encyclopaedia of Genes and Genomes
Additional file 5 Table S2 NanoString nCounter Custom CodeSet: 
C6959X1. *P < 0.05, **P < 0.01. #, number; CTRL, control; CUS, custom; FC, 
fold-change; HK, housekeeping; Hs, Homo sapiens; mRNA, messenger RNA; 
NEG, negative; POS, positive; sp., species
Additional file 6 Table S3 Neurone-, Astrocyte-, and Endothelial Cell-
Specific Transcripts. RMA, robust multi-array average
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